CommercialCoverageMedium impact
Varicocele: Selected Treatments (CPB 0413, reviewed 2026-06-30)
Aetna·Urology, Vascular Surgery, Radiology·Medical Policy
Effective date
Jun 30, 2026
We identified it
Aug 18, 2026
Summary
Aetna updated its varicocele treatment policy (CPB 0413, effective 2026-06-30) to specify covered indications for percutaneous embolization and ligation, while designating certain procedures as experimental/investigational. Billing teams must verify medical necessity criteria are met before processing claims and deny claims for subclinical varicocele, non-obstructive azoospermia, endovenous laser ablation, and sclerosant-augmented coil procedures.
Action Required
By 2026-06-30: Billing team must update billing system to enforce Aetna varicocele coverage criteria before claim submission. (1) For CPT 37241 and 55530/55540/55550: Require documentation of ONE of four covered conditions: adolescent grade 2-3 varicoceles with testicular growth retardation, male infertility with decreased sperm motility/concentration, post-surgical recurrence, or scrotal pain. (2) Deny all claims for CPT 37241, 55530, 55540, 55550 when diagnosis is N46.01-N46.022, N46.024-N46.029 (non-obstructive azoospermia) or for subclinical varicocele — these are non-covered. (3) Do not bill J1430 (sclerosant injection) with coil embolization; flag as experimental. (4) Do not bill endovenous laser ablation (EVLA) — no CPT code, but reject if documented in medical record. (5) Update encounter templates and prior auth checklists to prompt providers for specific covered indications. (6) Train front-line billing staff and prior auth personnel on the four covered criteria. Failure to validate medical necessity will result in claim denials from Aetna.